Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America.
The silver-haired bat variant of rabies virus (SHBRV) has been identified as the etiological agent of a number of recent human rabies cases in the United States that are unusual in not having been associated with any known history of conventional exposure. Comparison of the different biological and biochemical properties of isolates of this virus with those of a coyote street rabies virus (COSRV) revealed that there are unique features associated with SHBRV. In vitro studies showed that, while the susceptibility of neuroblastoma cells to infection by both viruses was similar, the infectivity of SHBRV was much higher than that of COSRV in fibroblasts (BHK-21) and epithelial cells (MA-104), particularly when these cells were kept at 34 degrees C. At this temperature, low pH-dependent fusion and cell-to-cell spread of virus is seen in BHK-21 cells infected with SHBRV but not with COSRV. It appears that SHBRV may possess an unique cellular tropism and the ability to replicate at lower temperature, allowing a more effective local replication in the dermis. This hypothesis is supported by in vivo results which showed that while SHBRV is less neurovirulent than COSRV when administered via the intramuscular or intranasal routes, both viruses are equally neuroinvasive if injected intracranially or intradermally. Consistent with the above findings, the amino acid sequences of the glycoproteins of SHBRV and COSRV were found to have substantial differences, particularly in the region that contains the putative toxic loop, which are reflected in marked differences in their antigenic composition. Nevertheless, an experimental rabies vaccine based on the Pittman Moore vaccine strain protected mice equally well from lethal doses of SHBRV and COSRV, suggesting that currently used vaccines should be effective in the postexposure prophylaxis of rabies due to SHBRV.
Morimoto
K
K
The Center for Neurovirology, Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107-6799, USA.
Patel
M
M
Corisdeo
S
S
Hooper
D C
DC
Fu
Z F
ZF
Rupprecht
C E
CE
Koprowski
H
H
Dietzschold
B
B
D000818:Animals; D000956:Antigens, Viral / Q000737:chemistry; D001483:Base Sequence; D001921:Brain / Q000821:virology; D002335:Carnivora / Q000821:virology; D002459:Cell Fusion; D002460:Cell Line; D002685:Chiroptera / Q000821:virology*; D006224:Cricetinae; D017931:DNA Primers; D014644:Genetic Variation; D006023:Glycoproteins / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D009447:Neuroblastoma; D009656:North America; D016133:Polymerase Chain Reaction; D011818:Rabies / Q000517:prevention & control / Q000821:virology*; D011819:Rabies Vaccines; D011820:Rabies virus / Q000235:genetics* / Q000302:isolation & purification / Q000502:physiology*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology; D017386:Sequence Homology, Amino Acid; D012867:Skin / Q000821:virology; D014407:Tumor Cells, Cultured; D014481:United States; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology; D014779:Virus Replication
D000956:Antigens, Viral; D017931:DNA Primers; D006023:Glycoproteins; D011819:Rabies Vaccines; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; C064951:glycoprotein G, Rabies virus